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Introduction
Treatment effects are often evaluated by comparing
change over time in outcome measures vs. placebo
or an active control. However, valid analyses of lon-
gitudinal data can be problematic, particularly when
some data are missing for reasons related to the vari-
able being analysed (1,2). Since the problem of miss-
ing data is almost ever-present in clinical trials,
numerous methods for analysing longitudinal data
and handling missingness have been proposed, exam-
ined and implemented (1–31).
Analyses of mean changes from baseline in clinical
trials have traditionally relied on simple methods
such as analysis of covariance (ancova) with missing
data imputed by carrying the last observation for-
ward (last observation carried forward, LOCF) or by
including only completers – those patients who had
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SUMMARY
Aims: Various analytical strategies for addressing missing data in clinical trials are
utilised in reporting study results. The most commonly used analytical methods
include the last observation carried forward (LOCF), observed case (OC) and the
mixed model for repeated measures (MMRM). Each method requires certain
assumptions regarding the characteristics of the missing data. If the assumptions
for any particular method are not valid, results from that method can be biased.
Results based on these different analytical methods can, therefore, be inconsistent,
thereby making interpretation of clinical study results confusing. In this investiga-
tion, we compare results from MMRM, LOCF and OC in order to illustrate the
potential biases and problems in interpretation. Methods: Data from an 8-month,
double-blind, randomised, placebo-controlled (placebo; n = 137), outpatient
depression clinical trial comparing a serotonin-noradrenalin reuptake inhibitor
(SNRI; n = 273) with a selective serotonin reuptake inhibitor (SSRI; n = 274) were
used. The study visit schedule included efﬁcacy and safety assessments weekly to
week 4, bi-weekly to week 8, and then monthly. Visitwise mean changes for the
17-item Hamilton Depression Rating Scale (HAMD17) Maier subscale (primary efﬁ-
cacy outcome), blood pressure, and body weight were analysed using LOCF,
MMRM and OC. Results: Last observation carried forward consistently underesti-
mated within-group mean changes in efﬁcacy (beneﬁt) and safety (risk) for both
drugs compared with MMRM, whereas OC tended to overestimate within-group
changes. Conclusions: Inferences are based on between-group comparisons.
Therefore, whether or not underestimating (overestimating) within-group changes
was conservative or anticonservative depended on the relative magnitude of the
bias in each treatment and on whether within-group changes represented improve-
ment or worsening. Preference should be given in analytic plans to methods whose
assumptions are more likely to be valid rather than relying on a method based on
the hope that its results, if biased, will be conservative.
What’s known
Missing data and the bias it can cause are almost
ever-present concerns in clinical trials. The last
observation carried forward (LOCF) and observed
case (OC) approaches have been common methods
of handling missing data in clinical trials and are
often speciﬁed in conjunction with analysis of
variance (anova) to assess longitudinal outcomes,
despite the fact that their use entails restrictive
assumptions that are unlikely to hold true.
Considerable advances in statistical methodology
and in our ability to implement those methods have
been made in recent years. More principled
approaches that require less restrictive assumptions
than LOCF and OC have gained widespread
acceptance because they are more robust to the
biases from missing data than LOCF and OC, and
therefore provide better control of false-positive
and false-negative errors. One of the newer
methods, increasingly referred to in the literature as
MMRM (mixed model for repeated measures), has
been studied extensively in the context of clinical
trials.
What’s new
Although the performance of MMRM compared
with LOCF is well characterised in the literature,
the emphasis has been on acute efﬁcacy outcomes.
With the increased popularity of MMRM, it is also
important to characterise results from MMRM,
LOCF and OC in safety outcomes and in long-term
studies. This investigation compared results from
efﬁcacy and safety outcomes in a long-term clinical
trial in major depressive disorder, thereby
illustrating how the beneﬁts of more robust
analyses such as MMRM can improve our
understanding of the risks and beneﬁts of drugs.
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OC). However, these approaches entail the restrictive
assumption that there is no relationship between
either the observed or unobserved outcomes for the
variable being analysed and the probability of drop-
out. This assumption is referred to in the statistical
literature as missing completely at random (MCAR).
In an efﬁcacy analysis, this assumption essentially
means that patients do not drop out for lack of efﬁ-
cacy. The LOCF approach further assumes that sub-
jects’ responses would have been constant from the
last observed value to the end-point of the trial.
These assumptions may not hold true in clinical
trials (6,12,13,19), and violations can confound
treatment with time (2), which in turn can bias
estimates of treatment effects and their standard
errors (SE) (2,6,9–13,19,21,22,25–27). It is often
assumed that the bias in LOCF leads to a ‘conserva-
tive’ analysis – that is, an underestimation of treat-
ment effects. Consider, for example, an efﬁcacy
measure. If patients drop out early – due to, say,
adverse events – mean change to end-point using
LOCF is assumed to lead to smaller (conservative)
mean changes because patient dropout occurred
before much meaningful improvement could occur.
Similarly, the bias in OC is often assumed to lead
to overestimation of treatment effects. Again, con-
sider an efﬁcacy measure. Patients who are not
responding well are more likely to drop out, leaving
only those patients who were responding well to
complete the study.
Although these assumptions may at ﬁrst look
appealing, closer inspection reveals several key issues.
Inferences are based upon comparisons between
treatment groups, not on the change within any one
group. Therefore, whether or not underestimating
(overestimating) within-group changes is conserva-
tive or anticonservative depends on the relative mag-
nitude of the bias in each treatment and on whether
within-group changes represented improvement or
worsening. For example, underestimating a treat-
ment’s effects might be conservative for an efﬁcacy
outcome in that we do not want to ascribe beneﬁt to
a treatment that does not in fact exist. However,
underestimating a treatment’s effects on a safety out-
come would be anticonservative because we do not
want to miss a signal regarding a potential safety
risk.
Therefore, it is not surprising that analytic
proofs (19,27) and studies in simulated data
(12,13,21,22,26,27,29,30) have clearly shown that
missing data can bias results, leading to both over-
estimation and underestimation of treatment
effects, with the direction and magnitude of bias
being difﬁcult to anticipate and dependent on
many factors. These conclusions are further sub-
stantiated by summaries of actual clinical trial data
(28).
A method increasingly referred to in the literature
as mixed model for repeated measures (MMRM) has
key theoretical advantages over LOCF and OC
(12,13,21,22,24,30,32,33). In an MMRM analysis,
data collected from all patients (those who drop out
as well as those who complete the study) are used to
predict mean longitudinal outcomes for the treat-
ment group. The theoretical origins of MMRM date
back many decades, but this method did not receive
extensive attention in the clinical trial literature until
roughly the past decade, when advances in comput-
ing capabilities made MMRM easy to implement.
The MMRM approach is one speciﬁc member of the
larger family of likelihood-based mixed-effects analy-
ses. This family of analyses offers a general frame-
work from which to develop longitudinal analyses
under less restrictive assumptions than LOCF and
OC. The speciﬁc details of an MMRM analysis are
chosen with the data characteristics of clinical trials
in mind. Other likelihood-based analyses with prop-
erties similar to MMRM have been referred to in the
literature as hierarchical models and random regres-
sion models. Multiple imputation (MI) is another of
the more modern analytic methods, but it uses a dif-
ferent approach to handling missing data than
MMRM. However, the theoretical underpinnings are
similar, and the two methods yield similar results in
actual practice (29).
The key difference between assumptions about
missing data in likelihood-based analyses such as
MMRM and in MI vs. the assumptions made by
LOCF and OC is that MMRM and MI allow for the
possibility that the observed outcomes for the vari-
able being analysed are related to the probability of
dropout. The speciﬁc assumption is referred to in
the statistical literature as missing at random (MAR).
The MAR assumption is often reasonable in clini-
cal trials as the observed data explain much of the
missingness in many scenarios (4,6,12,13,19,24). This
may be particularly true in well-controlled studies,
such as clinical trials, in which extensive efforts are
made to observe all the outcomes and the factors
that inﬂuence them (16).
Regardless, MAR is always more plausible than
MCAR because MAR is valid in every case when
MCAR is valid, but MCAR is not always valid when
MAR is valid.
Therefore, it is not surprising that numerous stud-
ies have reported that simple methods such as LOCF
and OC were not as robust to the biases from miss-
ing data as MMRM and similar methods
(2,5,6,10,12,13,15,19,21,22,25,26,29–31). In accor-
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papers from researchers with academic afﬁliations
(31,34), consensus papers from researchers with
industry afﬁliations (32), consensus papers from a
mix of academic and industry researchers (33,35),
and statistics text books (6,36) have all recom-
mended that analyses of longitudinal clinical trial
data move away from simple methods such as LOCF
and OC toward the MAR-based analyses, such as MI
and the likelihood-based family in which MMRM
resides.
Given this fundamental shift in analytic emphasis, it
is useful to characterise results from the newer, more
principled methods along with those of the LOCF and
OC approaches. Acute-phase efﬁcacy results from
MMRM and LOCF in actual clinical trial data have
been extensively summarized (12,13,19,21,22,24–
26,28,36). Hence, the purpose of this investigation was
to broaden the scope of comparisons to include results
from LOCF, OC and MMRM for safety and efﬁcacy
outcomes in a long-term clinical trial of patients with
major depressive disorder.
Methods
The study protocol was reviewed and approved by
the ethical review board at each centre, in accordance
with the principles of the Declaration of Helsinki,
and all patients provided written informed consent
prior to the administration of any study procedures
or treatment. Results from the a priori-deﬁned analy-
ses and additional details about the design of the
study used in our investigation have been reported
elsewhere (37,38). Key details about the design are
summarized here.
This study incorporated a double-blind, variable
expected duration placebo lead-in period; followed
by randomisation in a 2:2:1ratio to ﬁxed doses
of a serotonin-noradrenalin reuptake inhibitor
(SNRI), selective serotonin reuptake inhibitor (SSRI),
or placebo for an 8-week, acute-treatment period;
followed by a 6-month, double-blind, ﬂexible-dose
extension phase. Dose escalations for the active arms
and placebo rescue via randomisation to the active
treatments occurred based on predeﬁned blinded cri-
teria after the 8-week acute phase. The study visit
schedule included efﬁcacy and safety assessments
weekly to week 4, bi-weekly to week 8 and monthly
thereafter.
The trial had 684 patients with at least one post-
baseline observation (SNRI, n = 273; SSRI, n = 274;
placebo, n = 137). Study participants were outpa-
tients, 18 years of age or older, who met Diagnostic
and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) (39) criteria for major depressive
disorder (MDD), and had a Montgomery-Asberg
Depression Rating Scale (40) total score ‡ 22 and a
Clinical Global Impression of Severity (41) score ‡ 4
at the screening and second study visits. Exclusion
criteria included a current and primary Axis I disor-
der other than MDD; an Axis II disorder that could
interfere with protocol compliance; lack of response
of the current depressive episode to two or more
adequate courses of antidepressant therapy; serious
medical illness; a serious risk of suicide; a history of
substance dependence within the last 6 months, or a
positive urine drug screen. Concomitant medications
with primarily central nervous system activity were
not permitted.
For this investigation, visitwise mean changes for the
Maier subscale of the 17-item Hamilton Depression
Rating Scale (HAMD17) (42) (primary efﬁcacy out-
come), blood pressure and body weight were compared
using LOCF, MMRM and OC. In the LOCF analyses,
missing data were imputed by carrying the last observa-
tion forward, and mean changes at each visit were
assessed independently using an ancova model that
included the categorical effects of treatment and inves-
tigator, with baseline value included as a covariate. In
the OC analyses, the same ancova model was applied
independently to the observed data at each visit. The
MMRM analysis assessed data from all visits simulta-
neously using a restricted maximum-likelihood-based
approach. The model included the ﬁxed categorical
effects of treatment, investigator, visit and treatment-
by-visit interaction, with baseline value and the base-
line-by-visit interaction included as covariates. Within-
patient errors were modelled using an unstructured
(co)variance matrix. In all analyses, placebo-treated
patients were included until the visit at which they were
rescuedto active drug.Data from patients rescuedfrom
placebo to active drug are not included in the analyses
presented.
Similar to any mean change analyses, all analyses in
the present investigation assumed (approximate)
normality of the residuals. The OC and LOCF analyses
assumed that missing data arose from a completely
random mechanism (MCAR), whereas MMRM
assumed MAR. Additionally, LOCF assumed that the
values for patients who discontinued would not have
changed from the last observation to the end of the
trial, had they stayed in the trial. In this paper ‘signiﬁ-
cant’ or ‘statistically signiﬁcant’ refers to comparisons
with p £ 0.05. All analyses were conducted using sas
version 8 (SAS Institute Inc., Cary, NC, USA).
Results
Baseline demographic and illness characteristics are
summarized in Table 1. Randomisation resulted in
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according to any of the assessed demographic or ill-
ness characteristics.
The change in sample size over time is shown in
Figure 1. The percentage of patients completing the
8-week, acute-treatment period was 71.4% (195⁄273)
for the SNRI, 78.8% (216⁄274) for the SSRI and
73.0% (100⁄137) for placebo. These dropout rates of
21.2 (SSRI) to 28.6% (SNRI) are not unusual for
placebo-controlled, acute-treatment clinical trials in
MDD, and in fact are perhaps a bit lower than the
reported average dropout of 35% from the US FDA
summary basis of approval reports (43). Completion
percentages for the entire 8-month study were 38.5%
(105⁄273) for the SNRI and 45.3% (124⁄274) for the
SSRI. The impact of rescue for lack of efﬁcacy in the
placebo group was evident, as only 10.9% (15⁄137)
completed the trial.
Table 1 Baseline demographics and illness severity
SNRI
(n = 273)
SSRI
(n = 274)
Placebo
(n = 137)
Age, year, mean (SD) 41.1 (11.6)* 43.3 (13.0) 42.5 (12.3)
Age, year, range (minimum–maximum) 18–66 18–79 20–73
Gender, female, n (%) 173 (63.4) 186 (67.9) 87 (63.5)
Weight, kg, mean (SD) 83.0 (20.8) 83.4 (21.8) 87.5 (24.0)
Ethnic origin, n (%)
Caucasian 206 (75.5) 212 (77.4) 113 (82.5)
Hispanic 22 (8.1) 26 (9.5) 8 (5.8)
African-American 35 (12.8) 28 (10.2) 14 (10.2)
Asian 2 (0.7) 3 (1.1) 0 (0.0)
East Asian 3 (1.1) 1 (0.4) 0 (0.0)
Other 5 (1.8) 4 (1.5) 2 (1.5)
HAMD17 total score, mean (SD) 17.6 (4.8) 17.8 (5.1) 17.7 (5.2)
CGI-S score, mean (SD) 4.2 (0.7) 4.2 (0.7) 4.2 (0.7)
HAMA score, mean (SD) 14.1 (5.2) 14.6 (5.2) 14.4 (5.1)
SNRI, serotonin-noradrenalin reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; SD, standard deviation; HAMD17, 17-item
Hamilton Depression Rating Scale; CGI-S, Clinical Global Impression of Severity; HAMA, Hamilton Anxiety Rating Scale.
*The mean age of patients in the SNRI treatment group was statistically signiﬁcantly lower than that in the SSRI group (41.1 years vs.
43.3 years; p = 0.036). There were no other signiﬁcant between-group differences in baseline demographics or psychiatric proﬁle.
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Figure 1 Percentage of patients remaining at each time point during the 8-month study. Flexible dosing and rescue from
placebo were available after week 8. Rescue from placebo to active drug was based on investigator decision and lack of
response to placebo. Data from patients rescued from placebo to active drug were analysed separately and are not
presented here. SNRI, serotonin-noradrenalin reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor
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for all outcomes are summarized in Tables 2 and 3,
with mean changes over time for the HAMD17 Maier
subscale (efﬁcacy measure) depicted in Figure 2.
During the acute-treatment period (through week 8),
the two active-treatment arms can each be compared
with placebo at six visits, yielding 12 total compari-
sons vs. placebo. Focusing on the mean changes
(baseline to end-point) within each treatment group,
LOCF tended to yield the smallest mean changes,
with the greatest mean changes for OC, and MMRM
being intermediate (Table 2). However, inferences
are based on between-group changes, and across the
12 acute-phase comparisons, LOCF yielded 12 signif-
icant differences from placebo, compared with 10
signiﬁcant differences for OC and 11 for MMRM
(Figure 2). When including acute and extension peri-
ods, there are 24 opportunities to compare an active
drug with placebo. With LOCF, all 24 contrasts were
signiﬁcant, compared with 10 for OC and 15 for
MMRM. Although as suggested by Figure 2, the dif-
ferences in mean changes between the drugs and pla-
cebo were slightly greater with MMRM than they
were with LOCF, this was more than offset by
unduly small SE from LOCF that resulted from its
failure to account for the uncertainty of imputation.
Time-courses for mean changes from LOCF, OC
and MMRM analyses of systolic blood pressure, dia-
stolic blood pressure and body weight are shown in
Figures 3–5, respectively. Mean changes at week 8
and month 8 are further summarized in Table 2.
Across these various safety outcomes, LOCF and
MMRM generally agreed as to whether or not differ-
ences were statistically signiﬁcant, with OC yielding
fewer signiﬁcant differences than the other methods.
However, while LOCF consistently yielded the small-
est within-group mean changes, the greatest within-
group changes came from OC, with mean changes
from MMRM being intermediate in magnitude.
These general trends are exempliﬁed by the mean
changes to month 8 for body weight that are
depicted in Figure 5. Both LOCF and MMRM indi-
cated that the mean weight increase was greater for
the SSRI than for the SNRI. However, LOCF indi-
cated no weight gain from baseline and essentially no
difference from placebo at month 8 for the SNRI,
Table 2 Summary of acute and long-term efﬁcacy and safety outcomes by each analytical method
Assessment
LOCF, mean
change (SE)
MMRM, mean
change (SE)
OC, mean
change (SE)
HAMD17 Maier subscale, 8 weeks
SNRI ) 4.14 (0.23) ) 4.69 (0.24) ) 4.83 (0.25)
SSRI ) 3.92 (0.23) ) 4.24 (0.23) ) 4.24 (0.24)
Diastolic blood pressure (mm Hg), 8 weeks
SNRI + 0.73 (0.47) + 1.08 (0.53) + 1.24 (0.53)
SSRI ) 0.85 (0.47) ) 0.80 (0.51) ) 0.79 (0.50)
Systolic blood pressure (mm Hg), 8 weeks
SNRI + 1.26 (0.72) + 1.79 (0.79) + 2.10 (0.84)
SSRI ) 0.80 (0.71) ) 0.84 (0.76) ) 0.69 (0.80)
Weight (kg), 8 weeks
SNRI ) 1.01 (0.24) ) 1.04 (0.28) ) 1.15 (0.31)
SSRI ) 0.32 (0.24) ) 0.40 (0.27) ) 0.41 (0.29)
HAMD17 Maier subscale, 8 months
SNRI ) 4.71 (0.25) ) 6.39 (0.27) ) 6.94 (0.30)
SSRI ) 4.97 (0.25) ) 6.39 (0.25) ) 6.69 (0.27)
Diastolic blood pressure (mmHg), 8 months
SNRI + 0.72 (0.52) + 0.81 (0.70) + 1.04 (0.84)
SSRI + 0.04 (0.52) ) 0.24 (0.65) ) 0.54 (0.76)
Systolic blood pressure (mmHg), 8 months
SNRI + 2.48 (0.77) + 3.73 (1.14) + 4.10 (1.34)
SSRI + 0.17 (0.76) + 0.31 (1.06) + 0.01 (1.20)
Weight (kg), 8 months
SNRI 0.00 (0.26) + 0.61 (0.44) + 0.76 (0.53)
SSRI + 1.03 (0.25) + 1.83 (0.42) + 1.22 (0.48)
LOCF, last observation carried forward; SE, standard errors; MMRM, mixed model for repeated measures; OC, observed case; HAMD17,
17-item Hamilton Depression Rating Scale; SNRI, serotonin-noradrenalin reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
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the SSRI with a difference from placebo of 1.1 kg. In
contrast, MMRM indicated a mean increase from
baseline of 0.6 kg for the SNRI with a difference
from placebo of about 1.5 kg, and a mean increase
from baseline of 1.8 kg for the SSRI with a difference
from placebo of about 2.7 kg – a difference roughly
2.5 times greater than seen with LOCF. For systolic
Table 3 Summary of all statistically signiﬁcant contrasts
Week
1
Week
2
Week
3
Week
4
Week
6
Week
8
Week
12
Week
16
Week
20
Week
24
Week
28
Week
32
HAMD17 Maier subscale
SNRI vs. placebo LOCF * * * * * * * *****
SNRI vs. placebo OC * * * * * *
SNRI vs. placebo MMRM * * * * * * * *
SSRI vs. placebo LOCF * * * * * * * *****
SSRI vs. placebo OC * * * *
SSRI vs. placebo MMRM * * * * * * *
Systolic blood pressure
SNRI vs. placebo LOCF * * * *
SNRI vs. placebo OC * *
SNRI vs. placebo MMRM * * * * * *
SSRI vs. placebo LOCF
SSRI vs. placebo OC
SSRI vs. placebo MMRM
Diastolic blood pressure
SNRI vs. placebo LOCF
SNRI vs. placebo OC
SNRI vs. placebo MMRM
SSRI vs. placebo LOCF * * * *
SSRI vs. placebo OC *
SSRI vs. placebo MMRM *
Weight
SNRI vs. placebo LOCF * * * * * * *
SNRI vs. placebo OC * * * * * * *
SNRI vs. placebo MMRM * * * * *
SSRI vs. placebo LOCF ****
SSRI vs. placebo OC * * *
SSRI vs. placebo MMRM ****
HAMD17 Maier subscale
SSRI vs. SNRI LOCF *
SSRI vs. SNRI OC * *
SSRI vs. SNRI MMRM * *
Systolic blood pressure
SSRI vs. SNRI LOCF * * *****
SSRI vs. SNRI OC * * * *****
SSRI vs. SNRI MMRM * * * * * * * *
Diastolic blood pressure
SSRI vs. SNRI LOCF * * * * *
SSRI vs. SNRI OC * * * * * * *
SSRI vs. SNRI MMRM * * * * * *
Weight
SSRI vs. SNRI LOCF * * * * * * * *****
SSRI vs. SNRI OC * * * * * *
SSRI vs. SNRI MMRM * * * * * * *****
HAMD17, 17-item Hamilton Depression Rating Scale; SNRI, serotonin-noradrenalin reuptake inhibitor; LOCF, last observation carried
forward; OC, observed case; MMRM, mixed model for repeated measures; SSRI, selective serotonin reuptake inhibitor.
*p £ 0.05.
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greater for the SNRI than for the SSRI, with the
same general trend of LOCF showing smaller differ-
ences than MMRM. Observed case again tended to
show the greatest within-group changes.
Discussion
Dropout in clinical trials can arise from many factors
related to the pharmacology of the drug, such as lack
of efﬁcacy, loss of initially gained efﬁcacy due to
developed tolerance, lack of initial tolerability or
increased safety or tolerability issues over time.
Dropout can also arise from factors not related to
the drug, such as patients relocating and not being
able to return to research sites. Finally, dropout can
arise from unknown reasons; that is, loss to follow-
up.
Therefore, the direction and magnitude of bias
caused by missing data is difﬁcult to anticipate and
assess. We can only know the bias if we know the
true value; and if we know the true value, we have
no need to do the study. Nevertheless, missing data
has been an active area of investigation for many
years, and some general trends that can aid our con-
ceptual understanding have emerged. For example, in
an LOCF analysis, we assume that for patients who
have dropped out, no change would have been
observed from the point of dropout until end-point
had those patients continued in the trial. If patients’
data would have continued to improve (or worsen)
after dropout, then LOCF would underestimate the
average improvement (or worsening) within a partic-
ular treatment arm.
However, inferences regarding treatment effects
are based on comparisons with a control group, not
on changes within a single group. Therefore, the
direction and magnitude of the bias in an LOCF esti-
mate of a treatment’s effect depend on the relative
bias within the treatment group compared with the
control group, which in turn depends on, among
other things, the rate and timing of dropout in the
treatment group compared with the control group.
For example, holding all else equal, in scenarios in
which the overall tendency is for improvement, such
as in the acute symptomatic treatment of pain,
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Figure 2 Time-course of improvement on the HAMD17 Maier subscale by all the three analytical methods. Double-blind
placebo rescue was available after week 8. *p £ 0.05 vs. placebo; §p £ 0.05 SSRI vs. SNRI. LOCF, last observation carried
forward; OC, observed case; MMRM, mixed model for repeated measures; HAMD17, 17-item Hamilton Depression Rating
Scale
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timate an investigational drug’s advantage when
dropout is higher or earlier in the comparator and
underestimate its advantage when dropout is lower
or later in the comparator; and (ii) overestimate the
investigational drug’s advantage when the advantage
is maximum at intermediate time points and under-
estimate its advantage when the advantage increases
over time. For scenarios in which the overall ten-
dency is for worsening, such as in treating the cogni-
tive decline of Alzheimer’s disease, the above biases
are reversed (44).
It is important to note the caveat in the above
paragraph – holding all else constant. In actuality,
the bias due to LOCF depends on many factors. For
example, LOCF also assumes that the values of
patients who drop out carry the same weight as the
values of patients who stay in the trial. In addition,
the impact of rates and timing of dropout can be
enhanced or masked by rapid vs. slowly evolving
changes. Therefore, the magnitude and even the
direction of bias from LOCF in any one situation is
extremely difﬁcult, if not impossible, to determine.
The key assumption in an OC analysis is one of
the same assumptions of LOCF: namely, that the val-
ues of patients who drop out are not different from
those who stay in the trial. In many situations,
patients with favourable responses are more likely to
remain in the trial compared with those who have
an unfavourable response. Therefore, within any one
group, OC is likely to overestimate the change in
favourable outcomes and underestimate the change
in unfavourable outcomes. But, similar to LOCF, the
bias in the estimate of the difference between treat-
ment and control – which is the parameter of inter-
est – depends on many factors and is difﬁcult to
assess.
In contrast to LOCF and OC, MMRM does not
make assumptions about the patients that drop out.
Rather, MMRM uses the actual data from all patients
to predict what would have happened had patients
stayed in the trial under the assumption that the data
observed until the time of dropout is a useful predic-
tor of the data that was not observed.
Some researchers have argued for the use of what
is essentially an effectiveness analysis, where treat-
ment is considered successful if some reasonable
degree of improvement in efﬁcacy is observed and if
the patient completes the trial (45). The percentage
of successful outcomes can be compared between
4
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Figure 3 Time-course of change in systolic blood pressure by all the three analytical methods. Double-blind placebo rescue
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1154 Impact of Analytic Method on Interpretation of Outcomes
ª 2008 Eli Lilly and Company
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, August 2008, 62, 8, 1147–1158treatments, and since dropout is part of the out-
come, there is no argument about causal inference or
imputation.
However, the primary objective of most conﬁrma-
tory trials is efﬁcacy, not effectiveness (46). Further-
more, interpretation of results from an effectiveness
analysis is not clear with respect to safety outcomes.
For example, assume that in the present analysis, a
successful outcome on weight change is deﬁned as
gaining no more than 5% of baseline body weight
and completing the study. About 90% of placebo
patients would have an ‘unsuccessful’ weight change
outcome because they did not complete the trial,
whereas patients on the two active drugs would have
higher rates of success. This result would suggest that
placebo caused more weight gain than the active
drugs, a result counter to clinical experience and
common sense.
Results of the present investigation are generally
consistent with previous reports showing that, com-
pared with MMRM, LOCF yielded smaller within-
group mean changes in efﬁcacy (beneﬁt) and safety
(risk). OC tended to yield within-group mean
changes that were greater in magnitude than
MMRM. Regarding between-group changes, MMRM
tended to be intermediate to LOCF and OC, with
LOCF yielding the smallest between-group differ-
ences. Importantly, LOCF also tended to yield smaller
SE, and therefore, especially for the efﬁcacy outcome,
yielded more statistically signiﬁcant differences than
the other methods. An analysis using LOCF does not
distinguish between an actually observed data point
and one that is imputed. Therefore, SE for LOCF
mean changes at all time points are based on sample
sizes as if no patients dropped out. Mathematically,
this well-known bias in LOCF can result in SE that are
too small because the sample size is too large, which in
turn can exaggerate the statistical signiﬁcance. In other
words, we have more conﬁdence in the results than we
should because we think the sample size is larger than
it should be. This study and others have shown more
statistically signiﬁcant differences in efﬁcacy measures
between treatment groups for LOCF compared with
OC (47,48). Again, it is important to recognize that
whether or not underestimating (overestimating)
within-group changes is conservative or anticonserva-
tive depends on whether changes represent improve-
ment or worsening.
Although it is impossible to know which method
yielded results more closely reﬂecting the true treat-
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that MMRM is usually less biased by missing data
compared with LOCF or OC. Further, the differences
in results between the various methods seen in this
investigation could be clinically relevant. For exam-
ple, consider the mean changes in body weight at
month 8. With LOCF, the differences between pla-
cebo compared with the SNRI and placebo compared
with the SSRI were 0.1 and 1.1 kg, respectively. With
MMRM, the corresponding differences were approxi-
mately 1.5 and 2.7 kg. That is, with LOCF, the SNRI
appeared to be similar to placebo, and the SSRI had
a small mean weight increase. With MMRM, the dif-
ference between placebo and the SSRI was 2.5 times
the magnitude of the LOCF result. Similarly, the
increase in blood pressure for the SNRI vs. placebo
was twice the magnitude with MMRM compared
with LOCF. MMRM, however, does not universally
yield greater differences between drug and placebo
compared with LOCF. At the 8-week end-point for
the HAMD17 Maier subscale, LOCF and MMRM
yielded treatment contrasts vs. placebo that were
essentially identical, whereas at the 8-month end-
point, contrasts vs. placebo from LOCF were greater
than contrasts from MMRM.
Determining the clinical relevance of any mean
change result by itself is problematic. Individual
patient changes relative to baseline and, for safety
end-points, absolute values relative to normal ranges
must also be examined. However, the task of assess-
ing clinical relevance is not made easier when the
mean changes are potentially underestimated to the
degree seen in this study for some of the LOCF
safety results, or when results vary from one visit to
the next as seen in some of the OC results. A more
widespread use of MMRM and similar methods
should improve signal detection for both efﬁcacy and
safety outcomes, thereby yielding more consistent
assessments of risk and beneﬁt.
We have attempted to illustrate some of the
potential biases caused by assumptions in commonly
used analytical methods using data from a real clini-
cal trial. Perhaps the best proof of the biases in vari-
ous methods, however, comes from studies involving
simulated data where we know the true values. Inter-
ested readers may refer to several of the studies cited
in this report for detailed examples (12,13,21,22,
26,27,29,30).
Given that the present analyses were based on a
single clinical study, there are some noteworthy limi-
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shown across a wide variety of scenarios to be less
biased by missing data than LOCF or OC; however,
that does not guarantee that in every study the
results from MMRM will more closely reﬂect the
truth. Unlike in simulation studies, in this re-analysis
of actual clinical trial data, we do not know the true
differences between treatment groups. Therefore, it is
impossible to know whether MMRM yielded results
that more closely reﬂect the true treatment differ-
ences compared with LOCF or OC. Furthermore,
this investigation is limited in that it includes only
one study and may not necessarily reﬂect MDD trials
on the whole, and may not reﬂect what would be
seen in other disease states.
Use of MMRM is not a cure-all for the problems
caused by missing data. The only sure cure for miss-
ing data is to avoid the problem altogether. Indeed,
if there were no dropout, these three analytical meth-
ods (OC, LOCF and MMRM) would yield identical
results. In many areas of psychiatric research, how-
ever, we accept 30–40% rates of dropout (43) in
acute-phase trials as if nothing can be done.
Although avoiding missing data altogether is an
unattainable goal, more work is needed to under-
stand how to design and conduct trials to reduce the
rates of dropout as much as possible. In the mean-
time, when interpreting clinical trial results, it is
important to consider rates, timing and reasons for
dropout as well as the analytical methods. While we
wait for further advances in analyses and trial design,
it is comforting to know that use of MMRM in place
of LOCF and OC is clearly a step in the right direc-
tion with regard to better estimating longitudinal
treatment outcomes related to both efﬁcacy and
safety.
Conclusion
In this study, LOCF consistently underestimated
within-group changes in efﬁcacy (beneﬁt) and safety
(risk) for both drugs compared with MMRM, and
OC tended to overestimate within-group changes.
However, inferences are based on between-group
comparisons. Therefore, whether or not underesti-
mating (overestimating) within-group changes was
conservative or anticonservative depended on the
relative magnitude of the bias in each treatment and
on whether within-group changes represented
improvement or worsening. Comparing results from
efﬁcacy and safety outcomes illustrated how the ben-
eﬁts of more robust analyses such as MMRM can
improve our understanding of the risks and beneﬁts
of drugs.
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